RankingsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Common stock and paid-in capital

LIGAND PHARMACEUTICALS INC【LGND】

Market cap
$4B
P/E ratio
SummaryFinancials
Period EndCommon stock and paid-in capital (Million USD)YoY (%)
Dec 31, 2024337+69.79%
Dec 31, 2023199+34.62%
Dec 31, 2022148-60.43%
Dec 31, 2021373+17.15%
Dec 31, 2020318-13.33%
Dec 31, 2019367-53.57%
Dec 31, 2018791-0.89%
Dec 31, 2017798+3.71%
Dec 31, 2016770+16.29%
Dec 31, 2015662-2.76%
Dec 31, 2014681-5.20%
Dec 31, 2013718-4.46%
Dec 31, 2012752+2.57%
Dec 31, 2011733

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)